itamin D Analogs : Actions and Role in the reatment of Secondary Hyperparathyroidism

Although calcitriol has been shown to have an important role in the pathogenesis of hyperparathyroidism, its use as a therapeutic agent often has been limited by calcemic and phosphatemic toxicity. Vitamin D analogs and the synthetic prohormones, with the potential to have lesser effects on calcium and phosphorus, have been introduced and shown to be effective therapeutic agents. Paricalcitol is used widely in the United States and may be associated with improved clinical outcomes. Further studies on the effects of these vitamin D sterols on the skeleton and further studies of potential differential effects on calcification processes will be forthcoming, and as the mechanisms of their lesser toxicity become understood, perhaps this will pave the way for a future generation of vitamin D analogs with even greater specificity for the suppression of hyperparathyroidism with lesser toxicity. Semin Nephrol 24:456-459 © 2004 Elsevier Inc. All rights reserved.

[1]  M. Fukagawa,et al.  In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[3]  T. Akiba,et al.  Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  E. Slatopolsky,et al.  Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Y. Ohashi,et al.  Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  H. Mann,et al.  Alfacalcidol in the therapy of renal bone disease. , 2001, International journal of clinical pharmacology and therapeutics.

[7]  D. Batlle,et al.  Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  J. Valdin,et al.  A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. , 2001, Clinical nephrology.

[9]  Keith C. Norris,et al.  Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  Keith C. Norris,et al.  Intermittent doxercalciferol (1α-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism , 2000 .

[11]  T Saruta,et al.  Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  L. Avioli Vitamin D and the D-Hormones, Alfacalcidol and Calcitriol, as Therapeutic Agents for Osteoporotic Populations , 1999, Calcified Tissue International.

[13]  E. Slatopolsky,et al.  Vitamin D Analogs: Perspectives for Treatment , 1999, Mineral and Electrolyte Metabolism.

[14]  E. Slatopolsky,et al.  Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. , 1999, Journal of the American Society of Nephrology : JASN.

[15]  H. Malluche,et al.  22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. , 1999, Kidney international.

[16]  L. Hamm,et al.  Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Y. Ohashi,et al.  Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  E. Mawer,et al.  Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  A. Dusso,et al.  A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  E. Slatopolsky,et al.  A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  J. Kanis,et al.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure , 1995, BMJ.

[22]  T. Cundy,et al.  A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. , 1994, Journal of the American Society of Nephrology : JASN.

[23]  B. Carroll,et al.  Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. , 1994, Kidney international.

[24]  T. Kobayashi,et al.  The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats. , 1994, Journal of biochemistry.

[25]  J. Delmez,et al.  Pathogenesis of secondary hyperparathyroidism. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J. Delmez,et al.  Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  T. Mori,et al.  On the mechanisms for the selective action of vitamin D analogs. , 1991, Endocrinology.

[28]  T. Kobayashi,et al.  Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3. , 1989, Journal of nutritional science and vitaminology.

[29]  Keith C. Norris,et al.  Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. , 1989, The New England journal of medicine.

[30]  G. Hendy,et al.  Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. , 1989, Endocrinology.

[31]  J. Russell,et al.  Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. , 1986, Endocrinology.

[32]  J. Silver,et al.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. , 1986, The Journal of clinical investigation.

[33]  J. Russell,et al.  1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. , 1985, Endocrinology.

[34]  H. Harter,et al.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.

[35]  H. DeLuca,et al.  Antirachitic Activity of 1α-Hydroxyergocalciferol and 1α-Hydroxycholecalciferol in Rats , 1984 .

[36]  F. Marsh,et al.  Long-term experience of alfacalcidol in renal osteodystrophy. , 1982, The Quarterly journal of medicine.

[37]  A. Dusso,et al.  Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  A. Yoshitake,et al.  In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  K. Martin,et al.  Renal osteodystrophy: pathogenesis and management. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.